Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
FEBS Lett. 2010 Jun 3;584(11):2376-80. doi: 10.1016/j.febslet.2010.04.030. Epub 2010 Apr 18.
TL1A, a TNF member implicated in autoimmune diseases, is a transmembrane protein that is processed to release soluble TL1A (TL1A-S). TL1A-S induces a Th1 response, although the functional significance of membrane-bound TL1A (TL1A-M) remains unknown. We generated TL1A-M expression in HEK-293 cells capable of binding DR3-Fc. Co-incubating IL-12/IL-18-primed CD4(+) T cells with HEK-293 cells expressing TL1A-M induced 3-fold increase in IFN-gamma that was blocked by anti-TL1A Ab. These results demonstrate that TL1A-M can bind death domain receptor 3 (DR3) through cell-cell contact to induce downstream IFN-gamma secretion enhancement. Anti-TL1A antibodies designed to treat immune diseases should be verified to block both endogenous TL1A forms.
TL1A 是一种与自身免疫性疾病相关的 TNF 家族成员,是一种跨膜蛋白,经加工后可释放可溶性 TL1A(TL1A-S)。TL1A-S 可诱导 Th1 反应,尽管膜结合型 TL1A(TL1A-M)的功能意义尚不清楚。我们在能够与 DR3-Fc 结合的 HEK-293 细胞中生成 TL1A-M 表达。将 IL-12/IL-18 预刺激的 CD4(+) T 细胞与表达 TL1A-M 的 HEK-293 细胞共孵育可诱导 IFN-γ增加 3 倍,该作用可被抗 TL1A Ab 阻断。这些结果表明,TL1A-M 可通过细胞间接触与死亡域受体 3(DR3)结合,从而诱导下游 IFN-γ分泌增强。旨在治疗免疫性疾病的抗 TL1A 抗体应进行验证以阻断两种内源性 TL1A 形式。